Amedisys, Inc. (NASDAQ: AMED)(the “Company”), one of America's leading home health and hospice nursing companies, today released the results of a review conducted by Marwood Group Advisory, LLC (Marwood). Several months ago Amedisys engaged Marwood, one of the nation’s preeminent health care consulting firms, to provide an independent analysis of the Company’s procedures, controls, clinical infrastructure, corporate compliance processes, technology offerings and future strategies. Marwood conducted a review of academic research, over 11,000 pages of Company specific documents, interviews with 18 members of Company leadership, and interviews with a cross section of other home health providers from across the nation, and utilized its home health industry, legislative and regulatory knowledge to measure industry standards, best practices and leading practices to evaluate the Amedisys model and infrastructure. The results showed that Amedisys ranked highest compared to other publicly traded home health companies in terms of quality improvement and compliance processes. Among their findings, Marwood stated, “Amedisys also employs best practices in the areas of field clinician coding and accuracy, oversight and management infrastructure, corporate compliance, and care coordination technology.” They further state, “Based on our Quality and Compliance Process Scorecard and information collected during our review of Company documentation and onsite interviews, Marwood believes that, overall, Amedisys has implemented compliance and quality improvement processes that meet and/or exceed the industry average.”
The entire report has been posted to our website at www.amedisys.com.
“We are pleased with the results that Marwood found in their review of our Company,” stated William F. Borne, Chief Executive Officer. “We operate our Company with a view toward providing clinical excellence for our patients while maintaining effective compliance and controls, and these findings evidence our leadership in these and other measures.”